Actively Recruiting
Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Led by University of British Columbia · Updated on 2024-06-11
50
Participants Needed
1
Research Sites
176 weeks
Total Duration
On this page
Sponsors
U
University of British Columbia
Lead Sponsor
V
Vancouver Coastal Health
Collaborating Sponsor
AI-Summary
What this Trial Is About
The current first-line treatment for opioid use disorder (OUD) in Canada is buprenorphine/naloxone (bup/nx). The standard induction method of bup/nx requires patients to be abstinent from opioids and thereby experience withdrawal symptoms prior to induction, which can be a major barrier in starting treatment. Rapid micro-induction (also known as micro-dosing, low-dose induction) involves the administration of small, frequent does of bup/nx and removes the need for a period of withdrawal prior to the start of treatment. This study aims to compare the effectiveness and safety of rapid micro-induction versus standard induction of bup/nx in patients with OUD.
CONDITIONS
Official Title
Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have opioid use disorder as defined by DSM-5 criteria
- Seeking opioid agonist treatment
- Be 19 years of age or older
- Willing and able to follow the study protocol and schedule
- Able to provide written informed consent
- If female and able to have children, agree to use an approved birth control method during the study
You will not qualify if you...
- Have severe medical or psychiatric conditions that prevent use of buprenorphine/naloxone or hydromorphone
- Anticipate health worsening from stopping medications that conflict with the study drugs
- Positive pregnancy test if female and able to have children
- Used methadone or buprenorphine in the past 5 days
- Known allergy to buprenorphine/naloxone or hydromorphone
- May need unsafe pharmacological treatment during the trial
- Unwilling or unable to use approved birth control if female and able to have children
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9
Actively Recruiting
Research Team
P
Pouya Azar, MD, FRCPC, DABAM
CONTACT
J
James Wong, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here